10-K: Intensity Therapeutics 2025 10-K: Clinical Progress & Funding Challenges

Intensity Therapeutics' latest 10-K details clinical advancements for its lead cancer drug INT230-6, alongside significant operating losses and ongoing funding needs.

Summary

• Intensity Therapeutics is a late-stage clinical biotechnology company focused on localized cancer reduction and immune activation using its DfuseRx SM platform.
• The lead product candidate, INT230-6, is an intratumoral injection comprising cisplatin, vinblastine sulfate, and an amphiphilic molecule (SHAO) designed to disperse drugs within tumors.
• The company reported a net loss of $11.6 million for the year ended December 31, 2025, compared to $16.3 million in 2024.
• The accumulated deficit reached $78.4 million as of December 31, 2025.
• Cash and cash equivalents were $11.9 million as of December 31, 2025, projected to fund operations into the second quarter of 2027.
• The IT-01 Study (Phase 1/2 in metastatic cancers) completed enrollment in June 2022, with data showing a 75% disease control rate and median overall survival of 11.9 months in heavily pretreated patients. Sarcoma patients in this study showed a median overall survival of 21.3 months.
• The INVINCIBLE-2 Study (Phase 2 in early-stage breast cancer) completed enrollment in November 2023, demonstrating high necrosis (up to >95%) in presurgical breast cancer tumors and a favorable safety profile.
• The INVINCIBLE-3 Study (Phase 3 in metastatic soft tissue sarcoma) initiated in July 2024, enrolled 21 patients, but new site activations and patient enrollments were paused in March 2025 due to funding constraints.
• The INVINCIBLE-4 Study (Phase 2 in localized triple-negative breast cancer, TNBC) initiated in October 2024, paused new patient enrollment in September 2025 to revise the dosing regimen due to localized skin irritation. Preliminary data from 14 patients showed a 71.4% pathological complete response (pCR) rate in Cohort A (INT230-6 + SOC) vs. 33% in Cohort B (SOC alone).
• The company successfully developed Phase 3 quality analytical methods and manufactured large-scale batches of INT230-6, with an agreed CMC plan with the FDA for Phase 3 and product registration.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a high-risk, early-stage investment. While clinical data shows promising efficacy signals and a favorable safety profile for INT230-6, the significant financial distress, "going concern" warning, and pauses in critical clinical trials due to funding and safety issues present substantial headwinds. The company's reliance on future capital raises for continued operations and trial completion introduces considerable uncertainty.

Positives

• INT230-6 demonstrated a 75% disease control rate and 11.9 months median overall survival in heavily pretreated metastatic cancer patients in the IT-01 Study.
• Sarcoma patients in the IT-01 Study showed a median overall survival of 21.3 months, significantly exceeding historical benchmarks of 7.6 to 9.7 months.
• The INVINCIBLE-2 Study achieved high tumor necrosis (up to >95%) in presurgical breast cancer, with a favorable safety profile and increased immune cell infiltration (CD4+ and NK T-cells).
• Preliminary data from the INVINCIBLE-4 Study showed a 71.4% pCR rate in TNBC patients receiving INT230-6 plus standard of care, compared to 33% for standard of care alone.
• INT230-6 has an acceptable safety profile with mostly low-grade adverse events, and over 95% of the active agents remain in the tumor, minimizing systemic exposure.
• The company has established Phase 3 quality analytical methods and manufacturing processes for INT230-6, with an agreed CMC plan with the FDA.
• Orphan Drug Designation was granted by the FDA for INT230-6 (cisplatin, vinblastine sulfate, SHAO) for soft tissue sarcoma in June 2022, providing potential for seven years of marketing exclusivity.
• Strong intellectual property position with 19 issued patents globally, including 4 in the U.S., with expiration dates extending to 2033.
• Collaborations with NCI, Merck, Bristol Myers Squibb, Swiss Cancer Institute, and UniCancer for research and clinical trials.

Negatives

• Significant operating losses incurred since inception, with a net loss of $11.6 million in 2025 and an accumulated deficit of $78.4 million.
• The independent registered public accounting firm's report for 2025 contains a statement of "substantial doubt" about the company's ability to continue as a going concern due to recurring losses and negative cash flows.
• Operations are projected to be funded only into the second quarter of 2027, necessitating substantial additional funding.
• New site activations and patient enrollments for the INVINCIBLE-3 Study (Phase 3 Sarcoma) were paused in March 2025 due to funding constraints.
• New patient enrollment for the INVINCIBLE-4 Study (Phase 2 TNBC) was paused in September 2025 to revise the dosing regimen due to localized skin irritation.
• The company has limited experience conducting cancer clinical trials and has not completed a Phase 3 registration study.
• No revenue generated from product sales to date, and none expected in the foreseeable future.
• Reliance on third parties for manufacturing, with some components from sole-source suppliers, posing supply chain risks.
• The company has not entered into long-term manufacturing and supply agreements with any producers.
• The market price of common stock is highly volatile, and the company has a small public float.
• The company was not in compliance with Nasdaq's minimum bid price requirement in June 2025 and December 2025, though compliance was regained in March 2026.

Risks

• Market price volatility of common stock, potentially leading to loss of investment.
• Limited operating history and no revenue from product sales to date.
• Significant and anticipated continued operating losses, leading to substantial doubt about going concern.
• Need to raise substantial additional funding; inability to do so would force delays, reductions, or elimination of product development or commercialization efforts.
• Dependence on the success of new intratumoral technology, which requires additional development and may never receive regulatory approval or be commercialized.
• Risks and challenges in completing ongoing or future clinical trials, including patient enrollment difficulties, negative or inconclusive results, and regulatory delays.
• Intense competition from major pharmaceutical and biotechnology companies with greater resources.
• Uncertainty of obtaining and maintaining regulatory approval from the FDA and foreign authorities, which is a lengthy, complex, and expensive process.
• Limitations on marketing approved products to specific indications.
• Reliance on third parties for preclinical research, clinical trials, and manufacturing, with risks of unsatisfactory performance or supply disruptions.
• Dependence on sole-source suppliers for key product components (SHAO, cisplatin, vinblastine sulfate).
• Lack of long-term manufacturing and supply agreements.
• Limited experience in marketing and commercializing products.
• Potential for product liability claims or recalls.
• Dilution to existing stockholders from at-the-market (ATM) offerings.
• Failure to satisfy Nasdaq Capital Market listing requirements.
• Management's broad discretion in using cash and cash equivalents.
• No anticipated dividends in the foreseeable future.
• Provisions in charter documents and Delaware law may deter takeover efforts.
• Exclusive forum provisions in the certificate of incorporation may limit stockholders' ability to obtain a favorable judicial forum.
• Board's ability to issue additional common or preferred stock without stockholder consent, leading to dilution.
• Limitations on the utilization of net operating loss carryforwards due to IRC Section 382.
• Risks related to potential unauthorized disclosure or misappropriation of intellectual property by CROs.
• Impact of global, market, and economic conditions, including inflation, interest rates, geopolitical conflicts, and banking sector instability.
• Changes to U.S. tariff and import/export regulations.
• Potential for employees, consultants, and collaborators to engage in misconduct.
• Patent terms may be inadequate to protect competitive position.
• Inability to enforce intellectual property rights due to limited resources.
• Uncertainty regarding the enforceability of Russian patent due to military action.
• Healthcare legislative reform measures may negatively impact business and results of operations, including drug price negotiation and PBM reforms.
• Failure to comply with reporting and payment obligations under Medicaid Drug Rebate Program or other governmental pricing programs.

Future Outlook

The company expects to continue incurring significant expenses and operating losses for the foreseeable future as it advances clinical development, seeks regulatory approvals, develops manufacturing capabilities, and builds commercial infrastructure. It anticipates needing substantial additional funding beyond Q2 2027 to continue operations and pursue its growth strategy, which may involve further equity or debt financings, collaborations, or licensing arrangements. The company plans to restart site activations and patient enrollment in the INVINCIBLE-3 Study once sufficient funding is obtained and aims to resume enrollment in the INVINCIBLE-4 Study in Q2 2026, targeting completion by the end of 2027.

Management Comments

• "We are a late-stage clinical biotechnology company passionately committed to applying scientific leadership in the field of localized cancer reduction leading to anti-cancer immune activation."
• "We believe we have created a product candidate with the necessary chemistry to overcome this local delivery challenge within the tumor."
• "Our treatment concept pioneers a new dosing approach to treating cancer — kill tumors in the body (in situ) to create from the patient’s own cancer a recognizable, high-quality material (referred to as antigen) for better immune cell engagement against the cancer (immunological cell kill)."
• "Our objectives are to increase patient longevity, reduce side effects, remove the fear of treatment, empower the patient, and minimize the risk of disease recurrence."
• "We believe patients are highly interested in a product that can potentially destroy the majority of their tumor rapidly while waiting for their surgery and with the possibility to induce a systemic anti-cancer immune response."
• "We believe that RECIST measurements (longest diameter) are inappropriate to capture efficacy with INT230-6. As a result, overall survival, the FDA’s gold standard efficacy endpoint, is a better measure of INT230-6’s performance in metastatic cancer."
• "We believe that there is substantial doubt as to whether we can raise sufficient funding in order for us to continue operations."

Industry Context

StockSavvy.ai notes that Intensity Therapeutics operates in a highly competitive and rapidly evolving biopharmaceutical industry, particularly within immune-oncology. While many competitors like Amgen, Replimune, and others are focusing on intratumoral approaches that primarily stimulate immune cells, Intensity Therapeutics differentiates itself with a novel DfuseRx SM platform designed for direct tumor killing and subsequent immune activation, addressing the challenge of drug dispersion in the tumor microenvironment. The company's focus on overall survival as a primary endpoint for its Phase 3 sarcoma trial aligns with FDA's "gold standard" for efficacy, potentially offering a clearer path to approval compared to surrogate endpoints. However, the industry's increasing scrutiny on drug pricing and reimbursement, as evidenced by the Inflation Reduction Act and state-level initiatives, poses a significant challenge for all new market entrants, including Intensity Therapeutics.

Comparison to Industry Standards

• Sarcoma Treatment: The IT-01 Study's median overall survival of 21.3 months for sarcoma patients significantly exceeds typical median survival rates of 7.6 to 9.7 months for severe sarcomas, as reported in studies like Jones (2011), Cassier et al. (2014), and Subbiah et al. (2016). This suggests a potentially superior outcome compared to existing standard of care (SOC) drugs which have mOS ranging from 11 to 15 months in second and third-line settings.
• Drug Delivery: Intensity Therapeutics' DfuseRx SM technology addresses the challenge of water-based drug absorption in tumors, a limitation for many prior and current intratumoral treatments. This is a novel approach compared to competitors who may not sufficiently consider the tumor's lipophilic, high-pressure microenvironment.
• Safety Profile: The observed low-grade adverse events and minimal systemic exposure (over 95% drug retention in tumor) for INT230-6 compare favorably to the debilitating side effects normally associated with intravenous cisplatin and vinblastine sulfate at comparable doses.
• Efficacy Measurement: The company highlights that traditional RECIST criteria (measuring longest tumor diameter) may be inappropriate to capture efficacy with INT230-6 due to initial tumor swelling from drug absorption and immune cell infiltration, advocating for overall survival as a better measure. This contrasts with the standard industry practice of using RECIST 1.1 or iRECIST.
• Triple-Negative Breast Cancer (TNBC): Preliminary pCR rates of 71.4% for INT230-6 + SOC in the INVINCIBLE-4 study compare favorably to the 33% for SOC alone, suggesting a significant improvement over current treatments for this aggressive cancer type, which typically sees patients failing two lines of therapy progressing within nine weeks.

Management Changes

Corporate Governance

Legal Proceedings

• Currently not aware of any legal proceedings or claims that will have a material adverse effect on the business, financial condition, or operating results.

Related Party Transactions

• In October 2023, the company issued 3,200 warrants for consulting services to two shareholders, valued at $198,000.
• In April 2024, the company entered into a non-material agreement with a service organization controlled by a board member. For 2025 and 2024, the company expensed $49,910 and $42,110, respectively, and paid $49,910 and $40,310, respectively, to this organization for services.

Stakeholder Impact

• Shareholders: Face significant dilution risk from ongoing capital raises (ATM offerings, public offerings), high stock price volatility, and the "going concern" warning. Potential for long-term value if clinical trials succeed, but also risk of substantial loss.
• Employees: Compensation and benefits programs are in place, including equity compensation, 401(k) match, and health benefits. However, the company's financial instability and need for further funding could impact job security or future compensation.
• Patients: Potential for novel cancer treatments (INT230-6) for unmet medical needs, particularly in metastatic sarcoma and TNBC. Delays in clinical trials due to funding or safety concerns directly impact patient access to these potential therapies.
• Creditors: The "going concern" warning and recurring losses indicate increased risk for creditors.
• Suppliers/Contract Manufacturers: Reliance on third parties for manufacturing and clinical services means their operations are tied to the company's financial stability and ability to secure funding. Disruptions could impact their business.

Next Steps

• Obtain sufficient additional funding to restart site activations and patient enrollment in the INVINCIBLE-3 Study.
• Resume enrollment in the INVINCIBLE-4 Study in the second quarter of 2026, following protocol amendment approval.
• Target completion of enrollment for the INVINCIBLE-4 Study by the end of 2027, potentially adding resources to help sites enroll new patients.
• Continue treating all patients enrolled in the INVINCIBLE-3 Study during the pause.
• Publish data from the combination arms of the IT-01 Study with Merck.
• Execute the agreed-upon CMC plan with the FDA for Phase 3 and product registration.
• Seek regulatory approvals for product candidates that successfully complete clinical trials.
• Hire additional personnel and expand operational, financial, and management systems.
• Invest in measures to protect existing and new intellectual property.
• Establish a sales, marketing, medical affairs, and distribution infrastructure if marketing approval is obtained.
• Continue to monitor and comply with Nasdaq listing requirements.
• Lewis Bender, Joseph Talamo, and John Wesolowski have Rule 10b5-1 trading arrangements effective March 16, 2026, until November 13, 2026.

Key Dates

Recommendation

The filing presents a dire financial situation with a "substantial doubt" about the company's ability to continue as a going concern, coupled with recurring losses and negative cash flows. While clinical data shows promising efficacy signals for INT230-6, the pauses in two key clinical trials due to funding constraints and safety issues are significant setbacks. The urgent need for substantial additional capital, combined with ongoing dilution from equity raises and high stock price volatility, indicates a very high-risk investment. A seasoned investor would likely recommend selling to avoid further potential losses given the severe financial instability and operational challenges.

Keywords

Biotechnology, Cancer treatment, Intratumoral injection, INT230-6, Oncology, Clinical trials, Sarcoma, Breast cancer, Triple-negative breast cancer (TNBC), Immunotherapy, Drug development, SEC filing, 10-K, Financial reporting, Going concern, Capital raise, Orphan drug, Intellectual property, FDA approval, Pharmaceuticals